Treatment strategies for clear cell renal cell carcinoma: Past, present and future

Clear cell renal cell carcinoma (ccRCC) is the most prevalent histological subtype of kidney cancer, which is prone to metastasis, recurrence, and resistance to radiotherapy and chemotherapy. The burden it places on human health due to its refractory nature and rising incidence rate is substantial....

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 13; p. 1133832
Main Authors Yang, Junwei, Wang, Kuansong, Yang, Zhichun
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 21.03.2023
Subjects
clear cell renal cell carcinoma
cytokine
immune checkpoint inhibitor
obesity paradox
Oncology
renal cancer stem cells
tyrosine kinase inhibitor
cytokine
immune checkpoint inhibitor
clear cell renal cell carcinoma
renal cancer stem cells
obesity paradox
immunological substance modification
tyrosine kinase inhibitor
Online AccessGet full text

Cover

More Information
Summary:Clear cell renal cell carcinoma (ccRCC) is the most prevalent histological subtype of kidney cancer, which is prone to metastasis, recurrence, and resistance to radiotherapy and chemotherapy. The burden it places on human health due to its refractory nature and rising incidence rate is substantial. Researchers have recently determined the ccRCC risk factors and optimized the clinical therapy based on the disease's underlying molecular mechanisms. In this paper, we review the established clinical therapies and novel potential therapeutic approaches for ccRCC, and we support the importance of investigating novel therapeutic options in the context of combining established therapies as a research hotspot, with the goal of providing diversified therapeutic options that promise to address the issue of drug resistance, with a view to the early realization of precision medicine and individualized treatment.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Radu Pîrlog, University of Medicine and Pharmacy Iuliu Hatieganu, Romania; Marco Maruzzo, Veneto Institute of Oncology (IRCCS), Italy; Martin Klabusay, Palacký University, Olomouc, Czechia; Cosmin Andrei Cismaru, University of Medicine and Pharmacy Iuliu Hatieganu, Romania
Edited by: Ioana Berindan Neagoe, University of Medicine and Pharmacy Iuliu Hatieganu, Romania
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1133832